Gilead Sciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-06-22
- Employees
- 18K
- Market Cap
- -
- Website
- http://www.gilead.com
- Introduction
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Clinical Trials
690
Trial Phases
3 Phases
Drug Approvals
26
Drug Approvals
Emtricitabine and Tenofovir Alafenamide Fumarate Tablets（Ⅱ）
- Product Name
- 恩曲他滨丙酚替诺福韦片(Ⅱ)
- Approval Number
- 国药准字HJ20180067
- Approval Date
- Jun 19, 2023
Sacituzumab Govitecan for Injection
- Product Name
- 拓达维
- Approval Number
- 国药准字SJ20220015
- Approval Date
- Jun 7, 2022
Emtricitabine and Tenofovir Alafenamide Fumarate Tablets（Ⅱ）
- Product Name
- 恩曲他滨丙酚替诺福韦片(Ⅱ)
- Approval Number
- H20180067
- Approval Date
- Nov 21, 2018
Clinical Trials
Distribution across different clinical trial phases (566 trials with phase data)• Click on a phase to view related trials
News
Gilead and Kymera Partner on Novel CDK2 Molecular Glue Degrader for Cancer Treatment
Gilead Sciences and Kymera Therapeutics have entered into an exclusive option and license agreement to develop novel molecular glue degraders targeting CDK2 for cancer treatment.
U.S. Gene Therapy Market Projected to Reach $22.23 Billion by 2034, Growing at 19.8% CAGR
The U.S. gene therapy market is expected to grow from $4.37 billion in 2025 to $22.23 billion by 2034, driven by increasing investments, rising prevalence of chronic diseases, and integration of advanced technologies.
Isolated Viral Load Tests May Yield False Positives in Long-Acting PrEP Users
A recent study highlights that single viral load tests may produce false positive HIV results in individuals using long-acting injectable cabotegravir (CAB-LA) PrEP.
Cabotegravir Demonstrates Safety as HIV PrEP During Pregnancy
Long-acting injectable cabotegravir (CAB-LA) is shown to be safe and well-tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy.